Unknown

Dataset Information

0

Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study.


ABSTRACT: This open-label, multinational, pilot study randomized (1:2 ratio) adults with HIV-1 RNA <40 copies per milliliter and nucleos(t)ide-related safety/tolerability issues to switch to ritonavir-boosted atazanavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (n = 37) or the nucleos(t)ide reverse transcriptase inhibitor-sparing regimen of ATV/r plus raltegravir (RAL) (n = 72). At 24 weeks, 35/37 (94.6%) and 58/72 (80.6%) of patients, respectively, maintained virological suppression, the primary endpoint, and 1 (2.7%) and 7 (9.7%), respectively, experienced virological rebound. Corresponding 48-week proportions were 86.5%, 69.4%, 2.7%, and 12.5%, respectively. Adherence was lower and treatment discontinuation was higher with ATV/r+RAL. In conclusion, switching to ATV/r+RAL resulted in a higher virological rebound rate than switching to ATV/r plus tenofovir disoproxil fumarate/emtricitabine.

SUBMITTER: van Lunzen J 

PROVIDER: S-EPMC4804741 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study.

van Lunzen Jan J   Pozniak Anton A   Gatell Jose M JM   Antinori Andrea A   Klauck Isabelle I   Serrano Oscar O   Baakili Adyb A   Osiyemi Olayemi O   Sevinsky Heather H   Girard Pierre-Marie PM  

Journal of acquired immune deficiency syndromes (1999) 20160401 5


This open-label, multinational, pilot study randomized (1:2 ratio) adults with HIV-1 RNA <40 copies per milliliter and nucleos(t)ide-related safety/tolerability issues to switch to ritonavir-boosted atazanavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (n = 37) or the nucleos(t)ide reverse transcriptase inhibitor-sparing regimen of ATV/r plus raltegravir (RAL) (n = 72). At 24 weeks, 35/37 (94.6%) and 58/72 (80.6%) of patients, respectively, maintained virological suppression, the p  ...[more]

Similar Datasets

| S-EPMC3552169 | biostudies-literature
| S-EPMC6147473 | biostudies-literature
| S-EPMC4660025 | biostudies-literature
| S-EPMC4577040 | biostudies-literature
| S-EPMC6002106 | biostudies-literature
| S-EPMC7289135 | biostudies-literature
| S-EPMC4272445 | biostudies-literature
| S-EPMC4268426 | biostudies-literature
| S-EPMC5305227 | biostudies-literature
| S-EPMC9652537 | biostudies-literature